Drug Trial Radar · NCT05481333
A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
64
Actual
Start
Oct 24, 2022
Primary completion
Aug 29, 2023
Study completion Aug 29, 2023
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Aug 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) and subcutaneous (SC) doses of REGN7999 in healthy adult participants. The secondary objectives of the study are: * To characterize the drug concentration profile of single doses of IV or SC REGN7999 * To assess the immunogenicity of single ascending SC or IV doses of REGN7999
Conditions
- Healthy
Interventions
REGN7999Drug
Ascending IV or SC dose administered per protocol
PlaceboDrug
Ascending IV or SC dose administered per protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with REGN7999 or placeboTime frame: Through the end of study visit, week 20
- Incidence and severity of TEAEs in participants treated with REGN7999 or placeboTime frame: Through the end of study visit, week 26
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Drug Research Unit Gent
Ghent, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.